YERVOY®/ ™
(ipilimumab)

Patient Card

This Patient Card fulfills the conditions of the marketing authorisation and has been approved by the Medicines Authority
Date of Health Authority approval: April 2025
Local Approval Number: PromoMats **731-MT-2500001**

Bristol Myers Squibb®

IMPORTANT Information for Patients

Carry this card with you at all times to inform healthcare professionals that you are receiving treatment with YERVOY (ipilimumab) alone.

If you have any signs or symptoms, tell your doctor right away.

•	•
•	•
•	

POSSIBLE SIDE EFFECTS	
 **BOWEL AND STOMACH**	Diarrhoea (watery, loose or soft stools), bloody or dark-coloured stools, more frequent bowel movements than usual, pain or tenderness in your stomach or abdomen area, nausea or vomiting
 **EYE**	Redness in the eye, pain in the eye, vision problems or blurry vision
 **HORMONE GLANDS**	Rapid heartbeat, increased sweating, weight gain or loss, feeling cold, hair loss, constipation, your voice gets deeper, fever, tiredness, headache, dizziness or fainting, feeling more hungry or thirsty than usual, needing to urinate more often, or behavioural changes (e.g. less sex drive, being irritable or forgetful)
 **LIVER**	Eye or skin yellowing (jaundice), pain on the right side of your stomach area, dark urine, or bleeding
 **LUNGS**	Shortness of breath, cough or chest pain
 **NERVES**	Muscle weakness, numbness or tingling in legs, arms or face, dizziness, loss of consciousness or difficulty waking up
 **SKIN**	Skin rash with or without itching, dry skin, blisters and/or peeling of the skin, mouth sores, swelling of the face or lymph glands

Other important side effects:

Severe infusion reactions:

- Reactions to infusing ipilimumab into the bloodstream might occur, usually during or within 24 hours of receiving a dose.
- Tell your doctor or nurse right away if you get these symptoms during an infusion of ipilimumab: chills or shaking, itching or rash, flushing, difficulty breathing, dizziness, fever, and feeling like passing out.

IMPORTANT

- Tell your doctor of any previous medical conditions.
- Early treatment of side effects reduces the likelihood that ipilimumab treatment will need to be temporarily or permanently stopped.
- Signs and symptoms that may appear mild can quickly worsen if left untreated.
- **DO NOT** try to treat these symptoms yourself.
- Signs and symptoms may be delayed and may occur weeks to months after your last ipilimumab injection.

For more information, read the ipilimumab Package Leaflet at www.ema.europa.eu

IMPORTANT Information for Healthcare Professionals

- This patient is treated with ipilimumab monotherapy.
- Immune-related adverse reactions (irARs) may appear at any time during treatment or months after its discontinuation.
- Early diagnosis and appropriate management are essential to minimise life-threatening complications.
- Consultation with an oncologist or other medical specialist may be helpful for management of organ-specific irARs.
- Healthcare professionals should refer to the ipilimumab Summary of Product Characteristics (SmPC) at www.ema.europa.eu <or insert name of local labelling document and weblink as appropriate> or call Medical Information on <insert phone number> for more information.

The healthcare professional treating this patient with ipilimumab should complete the 'My Doctor's Contact Information' section of this Patient Card.

My Doctor's Contact Information (who prescribed ipilimumab)

Name of Doctor:

Office Phone:

After-Hours Phone:

My Contact Information
My Name and Phone:

Caregiver Name and Phone (in case of emergency):

Suspected Adverse Drug Reactions (side effects) or medication errors may be reported using the Medicines Authority ADR reporting form available online at http://www.medicinesauthority.gov.mt/adrportal and sent to the Pharmacovigilance Section at Post-Licensing Directorate, Medicines Authority, Sir Temi Żammit Buildings, Malta Life Sciences Park, San Ġwann SĠN or sent by email to: postlicensing.medicinesauthority@gov.mt

Suspected Adverse Drug Reactions (side effects) or medication errors can also be reported to AM Mangion Ltd on 00356 2397 6333 or by email to pv@ammangion.com